Tejon Ranch Co.
NYSE:TRCConglomerates
-$0.06 today
- Market cap
- $462.56M
- Beta
- 0.59
- P/E (TTM)
- 296.5
- EPS (TTM)
- $0.06
Volume 0.16M
Average 0.09M
TRC EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Tejon Ranch Co.NYSE: TRC
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $3.35M, compared with -$1.72M a year earlier. Trailing-twelve-month EBITDA was $14.14M. Over 3 fiscal years it compounded at -36.4% a year.
Context
- EBITDA amounted to 14.5% of revenue in FY2025, down 5.9 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $18.27M (+154.7%) for the fiscal year ending Dec 2026, a step up from the -16.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.35M-61.0% QoQ
- Last fiscal yearDec 2025
- $7.17M-16.1% YoY
- LTMMar 2026
- $14.14M+84.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +294.3% | +1240.5% | +946.2 pp |
| 1 year | -16.1% | +154.7% | +170.8 pp |
| 3-year CAGR | -36.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 7.17M USD
- Year-over-year change
- -16.1%
- 4-year CAGR
- -15.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.17M | -16.1% |
| FY2024 | 2024-12-31 | 8.55M | -17.8% |
| FY2023 | 2023-12-31 | 10.39M | -62.7% |
| FY2022 | 2022-12-31 | 27.83M | +102.3% |
| FY2021 | 2021-12-31 | 13.76M | — |
EBITDA vs competitors
How TRC compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +84.2% is the highest of 9, against a peer median of -35.2%.
- EBITDA amounts to 27.8% of revenue for TRC, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $173.92M USD | +1.5% | +11.6% | 76.5% | |
| LTM Apr 2026 | $81.29M USD | -72.0% | -35.9% | 5.3% | |
| LTM Mar 2026 | $38.14M USD | +9.9% | +56.4% | 4.3% | |
| LTM Mar 2026 | $30.36M USD | -85.1% | -41.7% | 1.6% | |
| LTM Mar 2026 | $14.14M USD | +84.2% | -36.4% | 27.8% | |
| LTM Apr 2026 | -$1.98M USD | -103.6% | — | 0.4% | |
| LTM Mar 2026 | -$4.62M USD | +60.4% | — | 0.5% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -$6.82M USD | +67.1% | — | 2.7% |
| LTM Mar 2026 | -$14.37M USD | -144.5% | — | 77.4% | |
| LTM Mar 2026 | -£325.37M GBP | — | — | — | |
| Peer median (excluding TRC) | — | -35.2% | -12.1% | 3.5% | |
Competitors are the stored peer set for TRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.61M | 79.22M | 44.74M | 41.89M | 49.59M |
| Cost of Revenue | 46.03M | 55.79M | 38.57M | 39.99M | 43.48M |
| Gross Profit | 9.58M | 23.43M | 6.17M | 1.89M | 6.11M |
| Gross Margin | 17.2% | 29.6% | 13.8% | 4.5% | 12.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 9.84M | 9.7M | 0 | 11.09M | 0 |
| Operating Expenses | 9.84M | 9.7M | 9.87M | 11.09M | 14.07M |
| Depreciation & Amortization | 4.59M | 4.63M | 4.81M | 4.89M | 6.01M |
| EBITDA | 13.76M | 27.83M | 10.39M | 8.55M | 7.17M |
| EBITDA Margin | 24.7% | 35.1% | 23.2% | 20.4% | 14.5% |
| Operating Income | (260K) | 13.73M | (3.7M) | (9.2M) | (7.95M) |
| Operating Margin | -0.5% | 17.3% | -8.3% | -22.0% | -16.0% |
| Interest Income | 0 | 0 | 0 | 2.27M | 914K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.42M | 9.47M | 9.29M | 12.86M | 9.11M |
| Income Before Tax | 9.16M | 23.2M | 5.59M | 3.66M | 1.16M |
| Pre-Tax Margin | 16.5% | 29.3% | 12.5% | 8.7% | 2.3% |
| Income Tax Expense | 3.82M | 7.39M | 2.32M | 976K | 1.09M |
| Net Income | 5.35M | 15.81M | 3.27M | 2.69M | 75K |
| Net Margin | 9.6% | 20.0% | 7.3% | 6.4% | 0.2% |
| EPS (Basic) | 0.20 | 0.60 | 0.12 | 0.10 | 0.00 |
| EPS (Diluted) | 0.20 | 0.59 | 0.12 | 0.10 | 0.00 |
| Weighted Avg Shares | 26.34M | 26.48M | 26.71M | 26.81M | 26.95M |
| Weighted Avg Shares (Diluted) | 26.41M | 26.65M | 26.71M | 26.82M | 26.95M |
Tejon Ranch Co.
NYSE:TRC
Intrinsic Alpha fair value
Locked
Current Price
$17.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.